The standard treatment for patients with early-stage prostate cancer are operation and radiotherapy. Stereotactic body radiation therapy (SBRT) is one of the new radiotherapy methods. The aim of the study was to analyze tumor control of prostate cancer patients treated with SBRT.
A prospective single-institution clinical study was conducted among previously untreated patients with histologically confirmed localized prostate cancer. Patients were treated with SBRT: 33.5 Gy in 5 fractions.
A total of 68 men with clinical stage of prostate cancer T1c-T2cN0M0 were included in the study. The median combined Gleason score was 6, the median PSA level was 10ng/mL. The median follow-up period was 48 months. Five years after the end of radiotherapy, the median PSA levels were as follows: 0.29ng/mL for all patients, 0.39ng/mL for those who did not receive androgen deprivation therapy, 0.25ng/mL for patients who underwent 6 months and 0.31ng/mL for patients who underwent 2-3 years of hormone therapy. Median nadir PSA levels were 0.025ng/mL for all patients and 0.48ng/mL for patients without hormone therapy. Low PSA nadir (<0.5ng/ml) was noted in 50% of patients without hormone therapy and in 70% of all other patients. Only in 4 patients (out of those who did not receive hormone therapy) PSA failure was observed (nadir plus 2ng/mL). No cases of PSA failure were noted among patients who underwent 6 months or 2-3 years of androgen deprivation therapy.
A good biochemical control was observed in prostate cancer patients treated with SBRT at 5 years follow-up.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 0000 Jan [Epub]
Monika Rucinska, Karolina Osowiecka, Anna Kieszkowska Grudny, Sergiusz Nawrocki
Department of Oncology, Collegium Medicum, School of Medicine, University of Warmia and Mazury in Olsztyn, Poland.